Work

Supplementary Figure 1 from Effect of Montanide and Poly-ICLC Adjuvant on Human Self/Tumor Antigen-Specific CD4+ T Cells in Phase I Overlapping Long Peptide Vaccine Trial

Year: 2023

Type: supplementary-materials

Abstract: PDF file - 13027K, Comparison of apparent avidities of NY-ESO-1-specific CD4+ T cells before and after vaccination. Apparent avidity (EC50) for recognition of the NY-ESO-1 assay OLP was determined for NY-ESO-1-specific CD4+ T cell lines before and after the vaccination. (A) Cohort 1 (OLP alone); (B) Cohort 2 (OLP in Montanide); and (C) Cohort 3 (OLP and poly-ICLC in Montanide).

DOI: 10.1158/2326-6066.22536316.v1

Authors: Takemasa Tsuji, Paul Sabbatini, Achim A. Jungbluth, Erika Ritter, Linda Pan, Gerd Ritter, Luis Ferran, David Spriggs, Andres M. Salazar, Sacha Gnjatic

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362628474

Cites:

Cited by:

Related to: 10